Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy

Area of Science:

• Hepatology
• Gastroenterology
• Pharmacology

Background:

• Hepatic encephalopathy (HE) presents a spectrum of neurological symptoms.
• Current treatments aim to reduce ammonia levels via production, absorption, or clearance.
• Gut-derived toxins contribute significantly to HE pathogenesis.

Purpose of the Study:

• To review the role of rifaximin in managing hepatic encephalopathy.
• To assess the efficacy of rifaximin in improving and preventing HE episodes.
• To highlight the need for further research on long-term rifaximin use and combination therapies.

Main Methods:

• Analysis of clinical trials investigating rifaximin for hepatic encephalopathy.
• Review of randomized controlled trials, including a large prevention trial.
• Consideration of concurrent treatments like lactulose and branched-chain amino acids.

Main Results:

• Rifaximin reduces ammonia production by gut bacteria, improving HE episodes.
• A major trial demonstrated rifaximin's efficacy in preventing recurrent HE.
• Most patients received concurrent lactulose treatment.

Conclusions:

• Rifaximin shows promise in managing hepatic encephalopathy by targeting gut-derived ammonia.
• High-quality trials are necessary to confirm long-term safety and efficacy.
• Further investigation into combination therapies for liver cirrhosis patients with HE is warranted.